Inhibition of sgk1 in the treatment of heart conditions
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsAnthony Rosenzweig, Saumya Das, Alan C. Rigby
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of SGK1, including Long QT syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by SGK1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure. The present invention also identifies selective inhibitors of SGK1. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of SG.
Claims20
A method for treating a subject for Long QT syndrome, comprising administering to the subject a therapeutically effective amount of at least one SGK1 inhibitor.
5-9. (canceled)
A method for treatment of a cardiovascular disease in a subject, the method comprising, administering to the subject a therapeutically effective amount of at least one SGK1 inhibitor, wherein the cardiovascular disease is selected from the group consisting of heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure.
12-18. (canceled)
Dependencies are inferred from the claim text.